drugset / Trial / NCT01019577
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.
Timeline
- Start
- 2005-10
- Primary completion
- 2007-07
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 50 mg/m2 | Intravenous |